Recent Company News

• 09:04 AM ET Apr 29, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 04:35 PM ET Apr 28, 2025
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 09:29 AM ET Apr 28, 2025
  

  CORRECTION: Akeso announced ivonescimab's NMPA approval in PD-L1 NSCLC/OS data on Friday (intraday US); comment published yesterday was a duplicate (HK$87.20, 0.00)

• 09:21 AM ET Apr 28, 2025
  

  StreetAccount Summary - US Pre-market trading update

• 08:18 AM ET Apr 28, 2025
  

  StreetAccount Summary - US Pre-market trading

• 08:03 PM ET Apr 27, 2025
  

  Akeso Inc receives NMPA approval for sNDA of ivonescimab for treatment of PD-L1-positive NSCLC in patients negative for EGFR and ALK gene mutations (HK$98.90, 0.00)

• 10:39 PM ET Apr 25, 2025
  

  StreetAccount Sector Summary - Healthcare Weekly Recap

• 02:54 PM ET Apr 25, 2025
  

  Summit Therapeutics comments on overall survival data from HARMONi-2 trial disclosed by Akeso ($23.21, -13.49)

• 02:30 PM ET Apr 25, 2025
  

  StreetAccount Summary: Notable Drug Events expected for the week of 27-Apr

• 01:30 PM ET Apr 25, 2025
  

  Akeso confirms ivonescimab receives NMPA approval for first-line treatment of PD-L1-positive NSCLC (HK$98.90, 0.00)